Hai‐Jie Hu
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research 20
- Peptidase Inhibition and Analysis 16
- Viral-associated cancers and disorders 11
- Inflammatory Biomarkers in Disease Prognosis 9
- Surgery top 5%
- Cholangiocarcinoma and Gallbladder Cancer Studies 70
- Pediatric Hepatobiliary Diseases and Treatments 12
-
- Gallbladder and Bile Duct Disorders 40
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis 11
- Co-authors
- Fu‐Yu LiWenjie MaTian‐Run LvYanwen JinFei LiuJun-Ke WangQin YangJun Yu
- Journals
- SHILAP Revista de lepidopterología (4 papers)Gastroenterology (1 paper)Hepatology (1 paper)
- Partner nations
- ChinaUnited StatesNepal
In The Last Decade
Hai‐Jie Hu
115 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 544
- Surgery 660
- Pulmonary and Respiratory Medicine 419
- Hepatology 79
- Cancer Research 148
Countries citing papers authored by Hai‐Jie Hu
This map shows the geographic impact of Hai‐Jie Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hai‐Jie Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hai‐Jie Hu more than expected).
Fields of papers citing papers by Hai‐Jie Hu
This network shows the impact of papers produced by Hai‐Jie Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hai‐Jie Hu. The network helps show where Hai‐Jie Hu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hai‐Jie Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 2 | |
| 5 | 2025 | 0 | |
| 6 | 2025 | 0 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 0 | |
| 9 | 2024 | 27 | |
| 10 | 2024 | 2 | |
| 11 | 2024 | 2 | |
| 12 | 2023 | 5 | |
| 13 | 2023 | 13 | |
| 14 | 2023 | 4 | |
| 15 | Organoids: The current status and biomedical applicationsbreakdown → | 2023 | 136 |
| 16 | 2023 | 1 | |
| 17 | 2020 | 24 | |
| 18 | 2019 | 10 | |
| 19 | 2019 | 6 | |
| 20 | 2018 | 7 |
About Hai‐Jie Hu
Hai‐Jie Hu is a scholar working on Oncology, Surgery and Hepatology, having authored 124 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (70 papers), Gallbladder and Bile Duct Disorders (40 papers), Pancreatic and Hepatic Oncology Research (20 papers), Peptidase Inhibition and Analysis (16 papers), Pediatric Hepatobiliary Diseases and Treatments (12 papers), Viral-associated cancers and disorders (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and Inflammatory Biomarkers in Disease Prognosis (9 papers). The work is most often cited by research in Oncology (544 citations), Surgery (660 citations) and Pulmonary and Respiratory Medicine (419 citations). Hai‐Jie Hu has collaborated with scholars based in China, United States and Nepal. Frequent co-authors include Fu‐Yu Li, Wenjie Ma, Tian‐Run Lv, Yanwen Jin, Fei Liu, Jun-Ke Wang, Qin Yang, Jun Yu, Tiantian Wang and Rongxing Zhou. Their work appears in journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.